Prothena: Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.
Read full article »
Prothena focuses on the development of novel protein immunotherapies for the treatment of cell adhesion.
Read more